Research in Dr. McConkey’s laboratory is focused on defining the molecular mechanisms involved in bladder cancer progression and developing novel therapies for muscle-invasive disease. In current efforts he is using whole genome approaches to define the molecular heterogeneity in muscle-invasive bladder cancers and defining the molecular mechanisms that dictate sensitivity and resistance to conventional cisplatin-based combination chemotherapy, EGFR and FGFR inhibitors, and proteasome inhibitors. He is Chair for Translational Medicine in the Southwest Oncology Group’s GU Subcommittee and has been actively involved in TCGA’s Bladder Cancer Analysis Working Group.
View all on Pubmed
Guo CC, Dadhania V, Zhang L, Majewski , Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur. Urol. 2016. e-Pub ahead of print. PMID: 26988609
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, McConkey DJ, Miller VA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasiv bladder cancer. Eur Urol. 2015:68(6):959-67. e-Pub ahead of print. PMCID: PMC4764095
McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Milikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol. 2016:69(5):855-62. PMCID: PMC4775435
Choi W, Porten S, Kim SH, Roth B, Cheng T, Willis D, Tran MN, Lee IL, Melquist J, Bondaruk JE, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014:25(2):152-65. PMCID: PMC4011497
The Cancer Genome Atlas research network contributed collectively to this study: Weinstein JN, Akbani R, Broom BM, Wang W, …McConkey DJ…. Comprehensive molecular characterization of urothelial carcinoma of the bladder. Nature. 2014:507(7492):315-22. PMCID: PMC3962515.